A global response to the chronic shortfall in antibiotic innovation is urgently needed to     combat antimicrobial resistance. Here, we introduce CARB-X, a new global publicâ€“private     partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
clinical trials     0.9999977804865428^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Clinical_trial        

antibacterial                 0.9996014890326982^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Antibacterial         

innovation                    0.9999994334256044^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Innovation            

portfolio                     0.9991857506640112^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Portfolio_(finance)   

antimicrobial resistance      0.9956175985371833^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Antibiotic_resistance 

chronic                       0.9998115638677212^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Chronic_(medicine)    

US                            0.8679567967876468^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/United_States         

antibiotic                    0.9999999999997158^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Antibacterial         

